Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research.

Dima M, Miller KA, Antico-Arciuch VG, Di Cristofano A.

Thyroid. 2011 Sep;21(9):1001-7. doi: 10.1089/thy.2011.0030. Epub 2011 Jul 18.

2.

PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.

Davies EJ, Marsh Durban V, Meniel V, Williams GT, Clarke AR.

J Pathol. 2014 May;233(1):27-38. doi: 10.1002/path.4312. Epub 2014 Jan 23.

PMID:
24293351
3.

Modeling anaplastic thyroid carcinoma in the mouse.

Champa D, Di Cristofano A.

Horm Cancer. 2015 Feb;6(1):37-44. doi: 10.1007/s12672-014-0208-8. Epub 2014 Nov 25. Review.

4.

Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A.

Cancer Res. 2009 Apr 15;69(8):3689-94. doi: 10.1158/0008-5472.CAN-09-0024. Epub 2009 Apr 7.

5.

Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.

Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y.

Mol Cancer Ther. 2010 Aug;9(8):2208-19. doi: 10.1158/1535-7163.MCT-10-0262. Epub 2010 Aug 3.

6.

Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.

Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, Refetoff S, Montagna C, Di Cristofano A.

Oncotarget. 2011 Dec;2(12):1109-26.

7.

Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G.

Endocr Relat Cancer. 2010 Jan 29;17(1):61-72. doi: 10.1677/ERC-08-0251. Print 2010 Mar.

8.

Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.

Soda G, Antonaci A, Bosco D, Nardoni S, Melis M.

J Exp Clin Cancer Res. 1999 Sep;18(3):363-7.

PMID:
10606183
9.

Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.

Powell DJ Jr, Russell JP, Li G, Kuo BA, Fidanza V, Huebner K, Rothstein JL.

Oncogene. 2001 May 31;20(25):3235-46.

10.

Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A.

Oncogene. 2010 Oct 21;29(42):5678-86. doi: 10.1038/onc.2010.308. Epub 2010 Aug 2.

11.

Mutation of the PIK3CA gene in anaplastic thyroid cancer.

García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M.

Cancer Res. 2005 Nov 15;65(22):10199-207.

12.
13.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

14.
15.

Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.

Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M.

Oncogene. 2006 Aug 31;25(39):5467-74. Epub 2006 Jun 19.

PMID:
16785999
16.

Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.

Wang HM, Huang YW, Huang JS, Wang CH, Kok VC, Hung CM, Chen HM, Tzen CY.

Ann Surg Oncol. 2007 Oct;14(10):3011-8. Epub 2007 Jul 20.

PMID:
17638058
17.

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.

Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F.

Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20. doi: 10.1007/s00280-012-1899-6. Epub 2012 Jun 9.

PMID:
22684718
18.

RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A.

Clin Cancer Res. 1998 Feb;4(2):287-94.

19.

Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.

Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges M, Murray NR, Fields AP.

Oncogene. 2014 Apr 17;33(16):2134-44. doi: 10.1038/onc.2013.147. Epub 2013 Apr 22.

20.

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.

Champa D, Russo MA, Liao XH, Refetoff S, Ghossein RA, Di Cristofano A.

Endocr Relat Cancer. 2014 Oct;21(5):755-67. doi: 10.1530/ERC-14-0268. Epub 2014 Jul 10.

Items per page

Supplemental Content

Write to the Help Desk